Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL794412 | 0.88 | KMT2A (0.62) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL289420 | 0.86 | KMT2A (0.60) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL22014371 | 0.86 | KMT2A (0.60) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL28448203 | 0.86 | HPGD (0.71) | TDP1KMT2ALMNAHPGDNPC1 | |
| SCHEMBL22015271 | 0.85 | LMNA (0.62) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL3960907 | 0.84 | KMT2A (0.62) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL30141105 | 0.84 | KMT2A (0.62) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL6282770 | 0.83 | KMT2A (0.81) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL27158539 | 0.82 | KMT2A (0.55) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL1347680 | 0.82 | L3MBTL1 (0.71) | TDP1KMT2ASLC6A2SLC6A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220009892-A1 | SUBSTITUTED PYRIDINE CARBOXYLIC ACIDS, THEIR PREPARATION METHOD AND COMPOSITIONS THEREOF | INCILIA THERAPEUTICS PRIVATE LIMITED (IN) | 2022-01-13 | — | — | US | disclosed |
| WO-2020100169-A1 | SUBSTITUTED PYRIDINE CARBOXYLIC ACIDS, THEIR PREPARATION METHOD AND COMPOSITIONS THEREOF | INCILIA THERAPEUTICS PRIVATE LIMITED (IN) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009892-A1 | SUBSTITUTED PYRIDINE CARBOXYLIC ACIDS, THEIR PREPARATION METHOD AND COMPOSITIONS THEREOF | PC, PCCA, GLS2 | TDP1 4115/4885KMT2A 2224/4885SLC6A2 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.